December 20, 2023
Otsuka Pharmaceutical said on December 19 that it has agreed to obtain the exclusive marketing rights in Europe for donidalorsen, an investigational hereditary angioedema (HAE) drug being developed by US RNA therapy specialist Ionis Pharmaceuticals. Under their licensing accord, Otsuka...read more